News
Current report No. 1/2021 – Positive results of the phase II clinical trial on Celon Pharma’s DPI esketamine in bipolar treatment-resistant depression [03KET2018]
Date prepared: 01/08/2021, 7:23 PM Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – confidential information. Content of the report: In relation to the current report No. 45/2020 regarding the date for the presentation of results of the phase II clinical trial on esketamine-based DPI drug (Falkieri) in bipolar treatment-resistant depression,Read more »
Celon Pharma at J.P. Morgan Annual Healthcare Conference DIGITAL 11-14 January 2021 .
This year, company taking meetings via the Bio Partnering platform during the week of the JP Morgan Healthcare Conference, but will also take part in meetings with foreign investors. Maciej Wieczorek, CEO of Celon Pharma: We have an intensive week of meetings and presentations ahead of us. This year, we use our presence at JPRead more »
TC with Members of the Board – 3Q2020 – results – webcast.
Celon Pharma at Jefferies Virtual London Healthcare Conference
The Company’s representatives will take part in the largest pharmaceutical conference in Europe. Maciej Wieczorek, CEO of Celon Pharma S.A.: We are increasing the presence of our products abroad, building a strong position in the segment of inhalation products on the global pharmaceutical market; we are observing that companies from around the world are takingRead more »
The power of science, passion and innovation – video material and on line meeting
Video about R&D Centre with transcript.
The experts agree. The targeted drug against COVID currently developed by Celon Pharma might change the course of the disease.
Thanks to its cutting-edge, innovative approach, Celon Pharma fast-tracks confirmation of the efficacy of its treatment against SARS-COV-2. The new therapeutic approach designed by scientists at Celon Pharma combines the previously dispersed possible responses to the threat brought about by SARS-COV-2. That approach assumes shortening of the infection duration in affected patients and significant limitationRead more »
Results of the PI3K delta study developed by Celon Pharma in the prestigious PLOS Magazine
Results of the PI3K delta study developed by Celon Pharma – CPL302-253 – have been published in the prestigious PLOS Magazine Preclinical characterization of CPL302-253, a selective inhibitor of PI3Kδ, as the candidate for the inhalatory treatment and prevention of Asthma presents the results of the development of a preclinical, highly specific and safe PI3KRead more »
Celon Pharma S.A. is the leader of the Forbes TOP25 of Tech-Medical Industry Ranking
Celon Pharma S.A. has become the leader of the ranking prepared by Forbes magazine. It is the largest, and, more importantly, the most mature biopharmaceutical company developing its own drugs – as justified by the authors of the report, who also underline the Company’s broadest and most advanced portfolio of innovative drugs among Polish biotechRead more »
Dr. Maciej Wieczorek among the speakers at the JAK Inhibitors Drug Development Summit 2020
The CEO of Celon Pharma will participate and hold a presentation at a summit devoted to clinical translation and optimisation of JAK inhibitors. It will also involve interdisciplinary discussions and panels aimed at developing effective JAK inhibitor development strategies and turning them into an effective response to unmet clinical needs of patients in various areas.Read more »
Celon Pharma at the GPW Innovation Day 2020
The GPW Innovation Day is a free-access conference during which representatives of companies operating in the field of new technologies, games or biotechnology meet with stock investors. This year, it will be held on-line on 23 and 24 June 2020. In the previous edition of the conference, the company presentations were participated by over 300Read more »
